352 related articles for article (PubMed ID: 28151719)
1. Neoadjuvant Enzalutamide Prior to Prostatectomy.
Montgomery B; Tretiakova MS; Joshua AM; Gleave ME; Fleshner N; Bubley GJ; Mostaghel EA; Chi KN; Lin DW; Sanda M; Novotny W; Wu K; Kantoff PW; Marck BT; Plymate S; Balk SP; Nelson PS; Matsumoto AM; Lis RT; Kibel A; Haas GP; Krivoshik A; Hannah A; Taplin ME
Clin Cancer Res; 2017 May; 23(9):2169-2176. PubMed ID: 28151719
[No Abstract] [Full Text] [Related]
2. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
Taplin ME; Montgomery B; Logothetis CJ; Bubley GJ; Richie JP; Dalkin BL; Sanda MG; Davis JW; Loda M; True LD; Troncoso P; Ye H; Lis RT; Marck BT; Matsumoto AM; Balk SP; Mostaghel EA; Penning TM; Nelson PS; Xie W; Jiang Z; Haqq CM; Tamae D; Tran N; Peng W; Kheoh T; Molina A; Kantoff PW
J Clin Oncol; 2014 Nov; 32(33):3705-15. PubMed ID: 25311217
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
McKay RR; Ye H; Xie W; Lis R; Calagua C; Zhang Z; Trinh QD; Chang SL; Harshman LC; Ross AE; Pienta KJ; Lin DW; Ellis WJ; Montgomery B; Chang P; Wagner AA; Bubley GJ; Kibel AS; Taplin ME
J Clin Oncol; 2019 Apr; 37(11):923-931. PubMed ID: 30811282
[TBL] [Abstract][Full Text] [Related]
4. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
5. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.
Freedland SJ; De Giorgi U; Gleave M; Rosbrook B; Shen Q; Sugg J; Haas GP; Shore ND
BMJ Open; 2021 Aug; 11(8):e046588. PubMed ID: 34385241
[TBL] [Abstract][Full Text] [Related]
6. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T
Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial.
Fleshner NE; Sayyid RK; Hansen AR; Chin JLK; Fernandes R; Winquist E; van der Kwast T; Sweet J; Lajkosz K; Kenk M; Hersey K; Veloso R; Berlin D; Herrera-Caceres JO; Sridhar S; Moussa M; Finelli A; Hamilton RJ; Kulkarni GS; Zlotta AR; Joshua AM
Clin Cancer Res; 2023 Oct; 29(19):3867-3874. PubMed ID: 37439809
[TBL] [Abstract][Full Text] [Related]
8. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
[TBL] [Abstract][Full Text] [Related]
9. Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response.
Karzai F; Walker SM; Wilkinson S; Madan RA; Shih JH; Merino MJ; Harmon SA; VanderWeele DJ; Cordes LM; Carrabba NV; Bright JR; Terrigino NT; Chun G; Bilusic M; Couvillon A; Hankin A; Williams MN; Lis RT; Ye H; Choyke PL; Gulley JL; Sowalsky AG; Turkbey B; Pinto PA; Dahut WL
Clin Cancer Res; 2021 Jan; 27(2):429-437. PubMed ID: 33023952
[TBL] [Abstract][Full Text] [Related]
10. [Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles].
Guan H; Ling ZX; Fang F; Mao LK; You ZH; Wang C; Chen SQ; Xu B; Chen M
Zhonghua Nan Ke Xue; 2018 Feb; 24(2):116-121. PubMed ID: 30156069
[TBL] [Abstract][Full Text] [Related]
11. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
Graham LS; True LD; Gulati R; Schade GR; Wright J; Grivas P; Yezefski T; Nega K; Alexander K; Hou WM; Yu EY; Montgomery B; Mostaghel EA; Matsumoto AA; Marck B; Sharifi N; Ellis WJ; Reder NP; Lin DW; Nelson PS; Schweizer MT
Prostate; 2021 May; 81(7):418-426. PubMed ID: 33755225
[TBL] [Abstract][Full Text] [Related]
12. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone.
Efstathiou E; Davis JW; Pisters L; Li W; Wen S; McMullin RP; Gormley M; Ricci D; Titus M; Hoang A; Zurita AJ; Tran N; Peng W; Kheoh T; Molina A; Troncoso P; Logothetis CJ
Eur Urol; 2019 Oct; 76(4):418-424. PubMed ID: 31176622
[TBL] [Abstract][Full Text] [Related]
14. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
[No Abstract] [Full Text] [Related]
15. Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
Emamekhoo H; Barata PC; Edwin NC; Woo KM; Grivas P; Garcia JA
Clin Genitourin Cancer; 2018 Dec; 16(6):429-436. PubMed ID: 30236961
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S;
J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308
[TBL] [Abstract][Full Text] [Related]
18. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
19. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
20. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
